ABAM Transitional Maintenance of Certification

Transitional Maintenance of Certification (tMOC) is a fundamental part of addiction medicine certification for current ABAM Diplomates. For more information or questions about the ABAM tMOC program, visit ABAM's website.

All of the courses below have been approved by the American Board of Addiction Medicine for tMOC.

ABAM tMOC Approved Courses

  • Feasibility and Effectiveness of Continuing Methadone Maintenance Treatment During Incarceration Compared With Forced Withdrawal (1CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about methadone maintenance treatment during incarceration from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about methadone maintenance treatment during incarceration from this journal article from The Journal of Addiction Medicine 2018.

    Learning objectives: 

    1. To identify the risks associated with forced withdrawal from methadone for inmates with opioid use disorder and barriers to continuing methadone maintenance treatment during incarceration in the U.S.
    2. To learn 3 or more logistical strategies for continuing methadone maintenance treatment during incarceration
    3. To recognize 3 or more benefits of continuing methadone for inmates with opioid use disorder, with regard to their behavior during incarceration and post-release


  • Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about buprenorphine treatment for adolescents and young adults from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about adolescent buprenorphine overdosing from this journal article from The Journal of Addiction Medicine 2018.

    Learning objectives: 

    1. Understand the limits of current scientific knowledge concerning best practices for treating adolescents and young adults with opioid use disorder.
    2. Learn clinically-relevant characteristics of adolescents and young adults with opioid use disorder.
    3. Gain insight into the evidence-based components of buprenorphine treatment programs and protocols that optimize treatment outcomes for adolescents and young adults with opioid use disorder.


  • The Nicotine Content of a Sample of E-cigarette Liquid Manufactured in the United States (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about nicotine content within e-cigarettes from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about nicotine content within e-cigarettes from this journal article from The Journal of Addiction Medicine 2018.

    Learning objectives: 

    1. Recognize the potential health concerns with e-cigarette use

    2. Understand the discrepancy between labelled vs. measured e-liquid concentrations

    3. List the impact of mislabeling e-liquid on those who use e-cigarettes


  • Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome? (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about maternal buprenorphine doses from this journal article from The Journal of Addiction Medicine 2018.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about maternal buprenorphine dose from this journal article from The Journal of Addiction Medicine 2018.

    Learning objectives: 

    1. Describe the study population, including maternal buprenorphine doses
    2. Describe study exclusions, including maternal urine drug screen results
    3. Describe which factors predict the need for morphine treatment of neonatal abstinence syndrome and which do not based on the article's findings



  • ASAM Review Course Spotlight Webinar Series 2018 (6 CME)

    Contains 24 Component(s), Medical Credits Offered

    Register now to earn a maximum of 6 CME while attending this six-webinar series, which will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2018. Topics include; psychiatric co-morbidities, cannabis, tobacco, prevention and public health, pharmacology and toxicology, and pain and addiction.

    image

    REVIEW COURSE ATTENDEES RECEIVE 25% OFF - Use the promo code located in your syllabus when checking out to take advantage of this special deal!

    Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine. 

    Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions have been collected in advance from participants of the 2018 Review Course and all attendees will have the opportunity to submit questions during the live webinar!

    All webinars will be recorded and available to watch for registrants unable to attend live. 

    DateTime (Eastern)
    Topic
    Tuesday, August 2812:00 pm – 1:00 pmCannabis
    Carla Marienfeld, MD
    Thursday, August 3012:00 pm – 1:00 pmTobacco
    Abigail Herron, DO, FAPA, DFASAM
    Wednesday, September 512:00 pm – 1:00 pmPrevention and Public Health
    Sharon Stancliff, MD, FASAM
    Friday, September 712:00 pm – 1:00 pmPharmacology and Toxicology
    Timothy Wiegand, MD, FACMT, FAACT
    Monday, September 1012:00 pm – 1:00 pmPain and Addiction
    Edwin Salsitz, MD, DFASAM
    Wednesday, September 1212:00 pm – 1:00 pmPsychiatric Co-Morbiditie
    Richard Ries, MD, DFASAM


    Additional Resources

    Additional Board Exam Preparation resources and tools are also available.


    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. 

    Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.  A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. 

    He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego. Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions. She previously worked at a large outpatient addiction treatment program serving over 5000 patients. Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders. She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction. During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships. She completed a fellowship in Addiction Psychiatry at Yale. During residency and her early faculty years, she founded and led the Yale Global Mental Health Program. She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry. She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program and a new Addiction Psychiatry Fellowship.

    Abigail J. Herron

    DO, DFASAM, FAPA

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  

    Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  

    Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. 

    Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 6 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

      The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

  • The ASAM Review Course in Addiction Medicine 2018 (20.5 CME)

    Contains 24 Product(s)

    Earn up to 20.5 CME while preparing for the ABPM Addiction Medicine Exam using this on-demand package of courses, containing the conference recordings, resources, practice questions, and slides from The ASAM Review Course in Addiction Medicine, 2018. The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    image

    Overview

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 600 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    Additional Resources

    Additional Board Exam Preparation resources and tools are also available.


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2018 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/25/2018, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Catherine Friedman, MD, FASAM, Chair
    • R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
    • Adam J. Gordon, MD, MPH, FACP, DFASAM
    • Zwaantje Hamming, FNP-C, CARN-AP
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM

    Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marcia Jackson, PhD

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients 
  • Pain Management and Opioids: Balancing Risks and Benefits (2.5 CME)

    Contains 5 Component(s), Medical Credits Offered

    Earn a maximum of 2.5 AMA PRA Category 1™ Credit(s) while reviewing prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.

    image

    The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 2000 to 2015 more than half a million people died from drug overdoses.
    • 91 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

    Learners will be able to:

    1. Accurately assess patients with pain for consideration of an opioid trial
    2. Establish realistic goals for pain management and restoration of function
    3. Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
    4. Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
    5. Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
    6. Educate patients about safe storage and disposal of opioids
    7. Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.  

    The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.  

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FAPA, DFASAM, Chair

    None

     

     

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    Zwaantje Hamming, FNP-C, CARN-AP

    None

     

     

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Sandy Metcalfe

    None

     

     

    Program Planning Committee

    Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

     

     

    Yngvild Olsen, MD, MPH

    None

     

     

    Theodore Parran, MD, FACP

    None

     

     

    Edwin Salsitz, MD, DFASAM

    None

     

     

    R. Corey Waller, MD, MS, FACEP

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

      ASAM CME Committee Reviewers

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

     

     

    Anthony H. Dekker, DO, DFASAM

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair

    Pfizer

    Johnson & Johnson

    Pfizer Canada

    Grant funding

    Consulting Fees

    Consulting Fees

     Principal Investigator

    Consulting

    Consulting

    Daniel Alford, MD, MPH

    None

     

     

    Michael Fingerhood, MD, FACP, FASAM

    None

     

     

    Catherine R. Friedman, MD, FAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Miriam S. Komaromy, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Mark P. Schwartz, MD, DFASAM

    None

     

     

    Mark A. Weiner, MD, FASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Jennifer L. Butchart

    None

     

     

    Penny S. Mills, MBA

    None

     

     

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 2.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    Acknowledgement

    Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

    RPC Commercial Support Disclosure Statement

    This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

    This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

  • Board Exam Study Tool (BEST) - 2018 (12 CME)

    Contains 5 Component(s), Medical Credits Offered

    Earn a maximum of 12 CME while learning from the BEST. This study tool helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.

    image

    The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format. 

    This powerful study tool includes: 

    1. Bank of 600 self-assessment questions reviewed for accuracy by addiction medicine experts
    2. Content derived from the ABPM Exam Blueprint for effective study guidance
    3. Excerpts and highlights from ASAM’s Essentials of Addiction Medicine and Principles of Addiction Medicine
    4. Glossary of important terms and definitions
    5. Additional resources recommended by Review Course faculty and experts for each topic
    6. 12 CME Credits upon completion
    7. Fully searchable functionality and content
    8. Access to the BEST 24/7 online at ASAM's e-Learning Center

    Live attendees of the 2018 ASAM Review Course in Addiction Medicine in Dallas, TX receive the 2018 BEST complimentary with registration. 

    Additional Board Exam Preparation resources and tools are also available.

    Goals and Objectives

    Upon completion of this education activity, participant should be able to:

    • Differentiate between important terms and definitions in the field of Addiction Medicine.
    • Distill knowledge on key points from the text, the Principles of Addiction Medicine, 5th edition and course slides
    • Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
    • Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.

    Participants of the 2018 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 12 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 12 AMA PRA Category 1 Credit(s)™ for completing this course.

  • ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science - 2018 (64.5 CME)

    Contains 49 Product(s)

    Earn a maximum of 64.5 AMA PRA Category 1™ credits while learning about the latest innovations in Addiction Medicine and Science from these on-demand conference recordings from the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.

    image

    Overview

    The ASAM 49th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2018 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two.  There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment. 

    Learning Objectives

    At the conclusion of the conference, participants should be able to:

    • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
    • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
    • Analyze new research and science to develop practical applications for treatment or further research.
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
    • Create a network of professionals or a set of resources that can be used to support the participant's practice.


    Accreditation Council for Continuing Medical Education (ACCME)

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    The ASAM 49th Annual Conference - Innovations in Addiction Medicine and Science

    The American Society of Addiction Medicine designates this enduring material for a maximum of 64.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (Tmoc)

    This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 64.5 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 49th Annual Conference – Innovations in Addiction Medicine and Science.

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Catherine Friedman, MD, FASAM, Chair
    • R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
    • Adam J. Gordon, MD, MPH, FACP, DFASAM
    • Zwaantje Hamming, FNP-C, CARN-AP
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM

    Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marica Jackson, PhD

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Who Should Attend:

    • Physicians and Clinicians
    • Researchers and Academics
    • Counselors and Students
    • Other Health Care Professionals 

    dedicated to increasing access and improving the quality of addiction treatment and care.

  • From Overdose to Engagement: Working with First Responders and Emergency Departments (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how professionals in Indiana's Project POINT have been removing as many barriers as possible to help patients get the services they desire, as well as, getting and then, maintaining engagement in treatment, from this conference recording at The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about how emergency department (ED) visits for opioid overdose have increased dramatically over the last several years, mirroring trends in overdose related mortality (1). In Indianapolis alone, our ambulance service—Indianapolis Emergency Medical Services—responded to over 2,000 opioid overdoses in 2016 and are on track to outpace that in 2017. Many local public health and safety agencies have championed increased access to naloxone and participated in trainings making it more widely available and accepted by first responders and community members (2). In Indianapolis, we created project POINT to help link those surviving an opioid overdose with the highest quality emergency care including warm hand offs to on-going treatment. Methods: We convened a group of experts and key stakeholders in our hospital system/community and undertook a quality improvement process to improve the care of overdose survivors while in the ED and through their transition to longitudinal care. Results: We developed a set of core ED services and a plan to implement each of them. Core ED services included: 1) brief assessment by a specialty trained outreach team member (ideally a recovery coach), 2) rapid HIV/hepatitis C testing, 3) naloxone teaching and provision, 3) harm reduction counseling, 4) referral to appropriate next level of care and 5) rapid ED follow up focused on recovery support, increasing/supporting motivation and overcoming logistical barriers. We also created a network of providers who were willing and able to accept our referrals and worked with them to optimize the referral process. 

    Conclusions: With the growing opioid epidemic, EDs and EMS systems are looking for novel and effective ways to reduce mortality and help bridge patients into recovery. EDs and EMS systems are used to working at all hours, in austere conditions with complex and often critically ill patients. We offer an expansive and largely untapped network of providers which could be brought to bear on this epidemic. Project POINT is one example of how the ED can help drive incremental change—even in areas of the country where access to high quality MAT is limited.

    Melissa A. Reyes

    MA, CRC

    Melissa Reyes, M.A., CRCMelissa Reyes completed her B.A. in Criminal Justice and Criminology at Ball State University in Muncie, IN. Following graduation, she worked as a case manager for the Madison Co. Problem Solving Courts for two years and was involved with both the Drug Court and Mental Health Court. In 2014, she then pursued her M.A. degree at Michigan State University in Rehabilitation Counseling. Melissa transitioned back to her home state of IN with the acceptance of a care coordinator position with Midtown Adult Addictions in Indianapolis, IN in September of 2016. The position was the forerunner of its kind for both organizations, and required constructing a unique collaboration between the community mental health center and Eskenazi Health ED; the area’s safety-net hospital. By January 2017, Melissa had accepted the role of Program Director for Project POINT (Planned Outreach,Intervention, Naloxone, and Treatment). Initially, POINT focused exclusively on providing referrals with warm handoffs, but Melissa expanded the scope and pursued a more holistic approach. This included promoting the start of implementing harm reduction counseling, rapid HIV/HCV testing as well as take home naloxone kits. In March of 2017, POINT expanded to include peer recovery coaching, and Melissa not only oversees the implementation of this new role, but also develops the training and supervision plan. Most recently, in January 2018, Melissa was offered and accepted the position of Project Director, Project POINT and Mobile Project POINT.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Treating Youth with Opioid Addiction: Cases and Controversies (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to treat youth with opioid addiction while employing developmentally specific approaches, using relapse prevention medication (MAT), from this conference recording from The ASAM 49th Annual Conference (2018). The session also includes when and how to involve families, as well as a discussion on issues in confidentiality and the use of various levels of care.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about more about treating youth with opioid addiction through cases and controversies. Young people are disproportionately affected by the current opioid epidemic, with catastrophic consequences for youth and their families. Despite the urgent need, there is a lack of consensus about treatment approaches for youth. Many practitioners have questions, and struggle with this “mysterious” and difficult to engage population. This workshop will feature an interactive, case-based format. Workshop leaders will present 4-5 cases with background and treatment course, each punctuated by “what would you do next…” management questions for guided discussion at several pivotal decision points in the course. Cases are chosen to reflect real world concerns and clinical conundrums, key learning objectives, practice debates and controversies. 

    The goal is to engage participants in a lively conversation about developmentally-informed strategies, approaches, and treatment options in the treatment of this critical target population. 

    Featured cases

    • 18 M at 5th episode of residential detoxification who has been unable to sustain continuing outpatient care despite previous course of buprenorphine.
    • 19 F who becomes pregnant during treatment with extended release naltrexone.
    • 20 M in outpatient treatment, abstinent from opioids on buprenorphine, but struggling with cocaine and other non-opioid substances, opposes communication with family.
    • 17 F who presents in crisis to residential treatment seeking detoxification, and struggles with the process of decision making around recommendations for and choice of relapse prevention medications (buprenorphine vs extended release naltrexone).
    • 18 M with sickle cell anemia with repeated relapses despite multiple treatment levels of care, including multiple attempts at outpatient buprenorphine treatment under various programmatic conditions.

    The case discussions will cover a range of questions, including: 

    1. developmentally specific approaches to treatment of adolescents and young adults with OUDs; 
    2. use of relapse prevention medication (MAT) in youth; 
    3. the role of families, when and how to involve them; 
    4. confidentiality; use of various levels of care; 
    5. the impact of other substance use disorders (primarily cannabis and alcohol); 
    6. delivery models for medications and psychosocial treatment modalities; and others.

    Marc Fishman

    MD, DFASAM

    Marc Fishman MD is a specialist in addiction psychiatry and addiction medicine. He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. 

    Dr. Fishman served as a co-editor for the most recent editions of ASAM's Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and also a current member of the Board.

    Bikash Sharma

    MD

    Bikash Sharma, MD is currently a medical director for adult services at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Sharma has board certifications with the American Board of Psychiatry and Neurology as well as the American Board of Addiction Psychiatry.  He has been published in numerous journals where he has written about opioid use disorders, and alcohol and substance use in African Americans.  


    Ann Bruner

    MD

    Ann Bruner, MD is a Medical Director, who treats youth at the Mountain Manor Baltimore, Maryland Treatment Centers.  Dr. Bruner is referenced as an author or co-author in dozens of peer-reviewed journals in the Journal of Adolescent Health, and a contributor to the Clinical Handbook of Adolescent Addiction.  

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Webinar: Addiction Medicine: The Next Generation (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathways physician will have to become board-certified in Addiction Medicine.

    Addiction Treatment Week

    This on-demand webinar will cover what an addiction medicine specialist looks like, the different settings an addiction medicine clinician can work in, and the future pathway physician have to become ADM certified.

    This webinar is ideal for pre-medical student, medical students, residents, and medical school administrators.

    Upon completion of this activity, participants will be able to:

    1. Explain recent updates to the Addiction Medicine field.
    2. Describe how changes to the certification process further integrate addiction treatment into the health care system.
    3. Appraise which pathways they are eligible to the ABPM ADM exam. 
    4. Define the different pathways a physician can take from to the ABPM exam. 
    5. Identify the need for more physicians to become board-certified in addiction medicine. 
    6. Explain the basic components of an addiction medicine specialist. 

    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Helen E. Jack

    MD

    Helen Jack is a fourth year student at Harvard Medical School. In medical school, her research has focused on how lay health workers, including recovery coaches and community health workers, can contribute to care access and outcomes. She also helps organize the Student Coalition on Addiction, a group of medical students from across Massachusetts engaged in advocacy on addiction medicine education and access to treatment services. She holds a Visiting Researcher position at the Institute of Psychology, Psychiatry, and Neuroscience at King's College London. With KCL, she conducts mental health systems research in Zimbabwe and works on a Wellcome Trust-funded project to build mental health research capacity in southern Africa. Helen graduated from Yale University in 2012. Following graduation, she got a second BA in Philosophy, Politics, and Economics at Oxford University as a Rhodes Scholar. 

    Anna Lembke

    MD, FASAM

    Dr. Anna Lembke is currently an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.  She is a diplomate of the American Board of Psychiatry and Neurology, a diplomate of the American Board of Addiction Medicine, the Program Director for the Stanford University Addiction Medicine Fellowship, and Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic.

    She has published peer-reviewed articles, chapters, and commentaries, including in the New England Journal of Medicine, the Journal of the American Medical Association, the Journal of General Internal Medicine, and Addiction. Dr. Lembke sees patients, teaches, and does research. She is the author of a book on the prescription drug epidemic: “Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop” (Johns Hopkins University Press, October 2016).


    Addiction Medicine:  The Next Generation Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Louis E. Baxter, MD, DFASAMNo Financial Relationships or Conflicts of Interest
    Helen JackNo Financial Relationships or Conflicts of Interest
    Anna Lembke, MD, FASAMNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Catherine Friedman, MD, FAPA, FASAM, Chair

    No Financial Relationships or Conflicts of Interest

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Webinar: Pathways to the Addiction Medicine Subspecialty (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will begin with an overview of the current state of the addiction epidemic, then move onto other topics including the gap in addiction treatment, the role physicians can play to help close the gap, and the importance, as well as how to apply for the ADM exam. Earn 1 CME while learning how to become board-certified in Addiction Medicine.

    Addiction Treatment Week

    This on-demand webinar will begin with an overview of the current state of the addiction epidemic and the huge gap in addiction treatment. It will then move on to the role physicians can play to help close this gap, and the importance to sit for the ABPM Addiction Medicine exam. The webinar will then move on to a representative from ABPM discussing the details of how physicians can apply for the ADM exam and any “lessons learned” from last year. 

    This webinar is ideal for any physician interested in addiction medicine, ABAM Diplomates, DATA 2000 waivered physicians, medical directors, and others.

    Upon completion of this activity, participants will be able to:

    1. Explain recent updates to the Addiction Medicine field.
    2. Describe how changes to the certification process further integrate addiction treatment into the health care system.
    3. Appraise which pathways they are eligible to the ABPM ADM exam. 
    4. Define the different pathways a physician can take from to the ABPM exam. 
    5. Identify the need for more physicians to become board-certified in addiction medicine. 

    Shawn A. Ryan

    MD, MBA, FASAM

    Shawn A. Ryan, MD, MBA is an Dual Board Certified Emergency Physician as well as Addiction Specialist.  He is currently an assistant professor, Department of Emergency Medicine, University of Cincinnati, and President & CMO of BrightView Health.  Dr. Ryan is currently practicing addiction medicine treatment in Cincinnati, is published on this issue, and also serves on many regional, state, and national committees addressing this complicated subject.  Dr. Ryan is President of the Ohio Society of Addiction Medicine and the Chair of Payer-Relations for ASAM and he spends a significant amount of time working with large commercial payers and Medicaid administrators on current and future payment strategies.

    Steven Daviss

    MD, DFAPA

    Steven Daviss, MD, DFAPA is a physician, double-boarded in Psychiatry and in Psychosomatic Medicine, which is the intersection of primary care and psychiatry. He is currently a senior medical advisor for the Office of the CMO at SAMSHA.  He is the past Chair of the Department of Psychiatry at Baltimore Washington Medical Center (2004-2014), and is a Clinical Assistant Professor in the University of Maryland School of Medicine, where he also attended medical school. He trained at the University of Pittsburgh Medical Center at Western Psychiatric Institute and Clinic. He completed an NIMH-funded clinical research fellowship in schizophrenia at the Maryland Psychiatric Research Center.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    Pathways to the Addiction Medicine Subspecialty Webinar Planning Committee 

    Name

    Disclosure

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM

    Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Mark P. Schwartz, MD, FAAFP, DFASAMNo Financial Relationships or Conflicts of Interest
    Shawn Ryan, MD, MBA, FASAMAdapt & Braeburn:  Consultant
    Steven Daviss, MD, DFAPANo Financial Relationships or Conflicts of Interest
    Michael Weaver, MD, DFASAMNo Financial Relationships or Conflicts of Interest

    ASAM CME Committee 

    Name

    Disclosure

    Catherine Friedman, MD, FAPA, FASAM, Chair

    No Financial Relationships or Conflicts of Interest

    Adam J. Gordon, MD, MPH, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Noel Ilogu, MD, MRCP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Herbert L. Malinoff, MD, FACP, DFASAM

    No Financial Relationships or Conflicts of Interest

    Edwin A. Salsitz, MD, DFASAM

    No Financial Relationships or Conflicts of Interest

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior, Honorarium, Speaker; BDSI, Honorarium, Consultant/SpeakerCommercial Interest Definition


    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Marijuana Legalization and Addiction Medicine: Global Perspectives (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about global developments pertinent to marijuana legalization and decriminalization efforts and the central role of addiction physicians in the respective public policies, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that, marijuana is an illegal drug in most countries around the globe, however efforts to legalize marijuana in a number of countries are gaining momentum. Addiction physicians are consequently are more involved in public policy debates on the subject. This symposium will provide an overview of global developments pertinent to marijuana legalization and decriminalization efforts and the central role of addiction physicians in the respective public policies. The increasing use and abuse of marijuana around the globe raises questions about the impact of this substance on communities, and the role of addiction physicians in influencing public policies. Questions about the safety, toxicity, addictive potential, gateway effects of marijuana are now being fiercely debated, as states in the USA (Colorado and Washington) are legalizing marijuana, and other countries are considering decriminalizing i.e. Uruguay. Furthermore, the "medical" use of marijuana is being permitted by some US states and nations (i.e. Canada). 

    The symposium speakers:

    1. Dr. Gregory Bunt will discuss decriminalization v. legalization of marijuana, 
    2. Dr. Susan Weiss will discuss cannabis policy developments at home and abroad, and 
    3. Dr. Kevin Sabet will cover international and global consequences of legalization of marijuana.In brief, the symposium will provide the participants an important historical and international perspective on marijuana use, abuse and dependency, and the relationship addiction physicians can establish with the public, policymakers and governmental authorities. In addition, an Audience Response System will be utilized to evaluate controversial opinions of participants and facilitate vigorous audience participation.

    Marc Galanter

    MD, DFASAM

    Marc Galanter, M.D., is a Professor of Psychiatry at NYU, Founding Director of the Division of Alcoholism and Drug Abuse, a Senior Editor of the Journal “Substance Abuse,” and co-editor of the American Psychiatric Association's “Textbook of Substance Abuse Treatment.” He has written four books, “Cults: Faith, Healing, and Coercion,” “Network Therapy for Alcohol and Drug Abuse,” “Spirituality and the Healthy Mind,” and "What is Alcoholics Anonymous?", and published over 200 peer-reviewed articles. His NIH and foundation-funded studies have addressed network therapy for substance abuse, pharmacologic treatment for addiction, the psychology of Twelve-Step recovery, and spirituality in healthcare.

    Dr. Galanter attended Albert Einstein College of Medicine where he did his residency in psychiatry. After that he was a Clinical Associate of the National Institute of Mental Health, then an NIH Career Teacher. He later served as President of the Association for Medical Education and Research in Substance Abuse (AMERSA, 1976-1977), the American Academy of Addiction Psychiatry (AAAP, 1991-1992), and the American Society of Addiction Medicine (ASAM, 1999-2001). Among his awards are the Gold Achievement Award for Innovation in Clinical Care, the Oskar Pfister Award for Spirituality, Religion and Psychiatry, and the Seymour Vestermark Award for Psychiatric Education, all from the American Psychiatric Association; the McGovern Award for Medical teaching from AMERSA; the Smithers Award for Research form ASAM; and New York State's Award for Psychiatric Research.

    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

    Gregory Bunt

    MD, FASAM, FISAM

    Dr. Gregory Bunt graduated medical school in 1983 from NYU School of Medicine, and completed his residency in Psychiatry at the Albert Einstein College of Medicine in 1987. He was among the first to complete the Fellowship in Addiction Psychiatry at NYU School of Medicine (1989), and has since been on the NYU Medical School Faculty in the Division of Alcoholism and Drug Abuse, currently as an Assistant Clinical Professor of Psychiatry. He is a diplomat of the American Board of Psychiatry and Neurology with Special Added Qualifications in Addiction Psychiatry and a Fellow of the International Society of Addiction Medicine.Dr. Bunt is the Immediate Past President of the New York Society of Addiction Medicine and the Immediate Past President of the International Society of Addiction Medicine. He has been the Medical Director for Daytop Village and Daytop International for over 25 years. He has authored over a dozen publications, and speaks nationally and internationally about addiction medicine and therapeutic communities.

    Kevin Sabet

    PhD

    Kevin A. Sabet, PhD, has studied, researched, written about, and implemented drug policy for almost 20 years. He has worked in the Clinton (2000) and Bush (2002-2003) Administrations, and in 2011 he stepped down after more than two years as the senior advisor to President Obama's drug control director, the only drug policy staffer to have ever served as a political appointee in a Democrat and Republican administration. He has appeared since at the Aspen Ideas and New Yorker festivals, on the Organization of American States blue ribbon commission advising hemispheric drug policy, and in hundreds of discussions promoting the ideas outlined in his first book, Reefer Sanity: Seven Great Myths About Marijuana. He has been featured on the front page of the New York Times and many publications and news channels. In 2013, he co-founded, Project SAM (Smart Approaches to Marijuana), which advocates for a public health based marijuana policy. He is also the Director of the Drug Policy Institute at the University of Florida, Department of Psychiatry, Division of Addiction Medicine and the author of numerous monographs and peer-reviewed journal articles and advises several non-governmental organizations as well as the United Nations and other multi-national organizations. Dr. Sabet's blog is housed at the Huffington Post and he regularly contributes to opinion-editorial pages, including the Washington Post and New York Times. Two of his op-eds have earned him a “Five Best Columns" distinction by The Atlantic. He is the winner of the 2014 Nils Bejerot Award for Global Drug Prevention, given at Stockholm City Hall by the anti-drug organization chaired by H.M. Queen Silvia of Sweden and the John P. McGovern Award for Drug Prevention given by the Institute for Behavior and Health, and Robert DuPont, the founding director of the National Institute on Drug Abuse. He received his Doctorate of Philosophy and Masters of Science from Oxford University as a Marshall Scholar in 2007 and 2002, respectively, and his B.A. with high honors in Political Science from the University of California, Berkeley in 2001.

    Susan R.B. Weiss

    PhD

    Dr. Susan Weiss is the Director, Division of Extramural Research at the National Institute on Drug Abuse (NIDA), which oversees NIDA’s extramural programs, research training, operations planning, and trans-NIH initiatives, such as the Adolescent Brain Cognitive Development (ABCD) study, and the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative. Dr. Weiss also serves as a senior science advisor to the NIDA Director and scientific liaison to the NIH, HHS, and other Federal Agencies. Previously, she served as the Chief of the Science Policy Branch and Acting Director of NIDA's Office of Science Policy and Communications.

    Before coming to NIDA, Dr. Weiss was the Senior Director of Research at the National Mental Health Association (now Mental Health America), and previously she directed a translational research program in the Biological Psychiatry Branch of the National Institute of Mental Health. 

    Dr. Weiss received multiple awards, including NIH Plain Language Awards, NIH and NIDA Director’s Awards, and an Emmy for her contributions to the HBO Addiction Project. She has published more than 150 scientific articles, graduated from SUNY at Stony Brook, and received her Ph.D. in Psychology from the University of Maryland. "

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Management of Pregnant/Parenting Women With Opioid Use Disorder and Their Infants (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder (OUD) and Their Infants, a clinical guide, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about the publication Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder (OUD) and Their Infants – a comprehensive Clinical Guide on managing optimal OUD care and treatment developed by the Substance Abuse and Mental Health Services Administration (SAMHSA). This Clinical Guide meets an urgent need among healthcare professionals who treat women with OUD and children exposed to substances by providing reliable information that can be applied in clinical practices to achieve positive outcomes for both mother and infant. It contains an introduction to the guide and fact sheets that include clinical scenarios, clinical action steps, supporting evidence, clinical considerations, and web resources. 

    The factsheets are organized into three sections: 

    • Section I – Prenatal Care (Factsheets #1–8)
    • Section II – Infant Care (Factsheets #9–13) 
    • Section III – Maternal Postnatal Care (Factsheets #14–16) 

    The Clinical Guide is based on the recommendations published in Advancing the Care of Pregnant and Parenting Women With Opioid Use Disorder and Their Infants: A Foundation for Clinical Guidance

    This workshop will be moderated by Melinda Campopiano, MD, Medical Officer for SAMHSA’s Center for Substance Abuse Treatment. She and three members from the RAND/UCLA Appropriateness Method (RAM) expert panel will discuss treatment recommendations from the Clinical Guide. Audience members will have the opportunity to ask questions about the recommendations and the clinical care for pregnant and parenting women with OUD.

    Charles W. Schauberger

    MD, MS, CPE

    Dr. Charles Schauberger is an obstetrician who practices at Gundersen Health System in La Crosse, Wisconsin. He attended University of Iowa Medical School and completed a residency in Obstetrics & Gynecology at the same location many years ago. He received a MS in Administrative Medicine from the University of Wisconsin- Madison. He has published over 40 articles in the peer review literature. He is passionate about the care of pregnant women with addictions.

    Hendree Jones

    PhD

    Hendree Jones, PhD is a Professor in the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill and Executive Director of Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. She is also an Adjunct Professor in the Department of Psychology, UNC, Chapel Hill and an Adjunct Professor in the Psychiatry and Behavioral Sciences and in the Department of Obstetrics and Gynecology, School of Medicine, Johns Hopkins University. 

    Dr. Jones is an internationally recognized expert in the development and examination of both behavioral and pharmacologic treatments for pregnant women and their children in risky life situations. Dr. Jones has received continuous funding from the United States National Institutes of Health since 1994 and has published over 185 publications, two books on treating substance use disorders (one for pregnant and parenting women and the other for a more general population of patients), numerous book and textbook chapters. She is a consultant for SAMHSA, the United Nations and the World Health Organization. 

    Dr. Jones leads or is involved in projects in Afghanistan, the South America, the Republic of Georgia, South Africa, and the United States which are focused on improving the lives of children, women and families.

    Diana Coffa

    MD

    Dr. Coffa is the Residency Program Director for the Family and Community Medicine Residency program at the University of California, San Francisco. in addition to practicing full spectrum primary care, Dr. Coffa co-leads an addiction consultation clinic and directs the chronic pain programs at the Family Health Center, an FQHC teaching clinic. She oversees the clinic's buprenorphine program and ensures that residents in family medicine, internal medicine, pediatrics, obstetrics, and psychiatry have access to buprenorphine training. She is also the primary consultant for buprenorphine prescribing at Zuckerberg San Francisco General Hospital, providing clinical guidance to hospital and maternal care providers who are treating hospitlalized patients for opioid use disorder.

    Anthony Campbell

    RPH, DO, CDR, USPHS

    Dr. Anthony Campbell is currently a board eligible candidate in the field of addiction medicine who currently services as a Clinical Specialty Consultant with the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment in the Division of Pharmacologic Therapies (SAMHSA/CSAT/DPT). He and serves as a Commander in the United States Public Health Service. In his role at SAMHSA, he is responsible for planning, directing and evaluating the development of pharmacotherapy-based treatment standards and guidelines that require specialized DPT medical review. In addition he is an adjunct professor at both Howard University Colleges of Pharmacy and Medicine in Washington DC.

    Dr. Campbell earned two bachelor’s degrees from Howard University; Chemistry (85) and Pharmacy (88). He earned his Doctorate of Osteopathic Medicine from Ohio University (94). Additional training followed including a residency in Internal Medicine, with current board certification.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Harm Reduction for Patients Prescribed Buprenorphine: Is it Possible? (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning harm reduction strategies and keeping people engaged in care, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that the hallmark of addiction is loss of control and ongoing compulsive substance use despite negative consequences, and is underscored by significant difficulty in executive functioning and organization. As such, especially early on in care or at a time of relapse, highly structured treatment modalities and scheduling are unrealistic for many at best, and potentially lethal for others at worst. If late or missed appointments result in longer waits or missed opportunities for care, or substance use results in discharge from care or referral to a higher level of care when the patient is either not able or ready to make such a change, the result can be no level of care. Despite the prescription drug monitoring program, misuse deterrent opioid formulations, expanded education efforts for safe pain prescribing and SUD screening and management, increased buprenorphine trainings and expanded waivers, the substance use disorder treatment gap remains and the opioid overdose epidemic continues to soar. The landscape of the opioid epidemic has changed even more dramatically with fentanyl and carfentanyl, requiring more readily available care, and flexible care models to help keep people engaged in care, while we work with them through the natural history of substance use disorder. By partnering with them in this manner, we help keep patients alive, lower their risk of ongoing serious health complications or overdose, and increase their chances of continuing to engage in meaningful treatment; we collaborate with them in the practice of harm reduction.

    Laura Kehoe

    MD, MPH, FASAM

    Laura Kehoe, MD, MPH, FASAM, is a medical director at the Bridge Clinic, Substance Use Disorder Initiative, for the Massachusetts General Hospital.  Dr. Kehoe is also Assistant Professor of Medicine at Harvard Medical School and is board certified in both Internal Medicine and Addiction Medicine. She attended Tufts University School of Medicine and Boston University School of Public Health and completed her residency in Internal Medicine at Massachusetts General Hospital. At Massachusetts General Hospital, she is the Medical Director of the Substance Use Disorder Bridge Clinic, an innovative, “on demand,” urgent care addiction program, and an attending physician on the inpatient Addiction Consult Team (ACT). In addition, she is the co-chair of the hospital-wide Substance Use Disorder Education Committee, where she works with other team members to expand evidence-based treatment of patients with addiction, and is actively involved in resident physician training.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Teaching Substance Use Disorders to Millennial Learners (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about educational best practices for creating and implementing new SUD-focused curriculum for millennial learners, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that the question of how to craft curricula to engage residents on Substance Use Disorders topics is both difficult and urgent.  It is difficult because there is a paucity of research on the efficacy of various didactic formats to guide us towards solutions; urgent because we are increasingly identifying knowledge gaps among residents in critical SUDs topics. Using as a model the new Substance Use Disorders Theme Block from the MGH Internal Medicine residency, this workshop seeks to spark discussion among educators about best practices for the creation and implementation of new SUDs-focused curricula for millennial learners. Through group discussions, video review of sessions, and microskills teaching, facilitators will explore how educators can expand the diversity of didactic formats, integrate Buprenorphine waiver training, and include peer-developed and peer-delivered content in their SUDs curricula. Throughout the session, participants will be exposed to different ways of gathering real-time and actionable feedback from residents. 

    The workshop begins with a brief interactive review of literature on the impact of different didactic formats on medical student and resident engagement and confidence, and explores the different didactic formats used in the MGH SUDs Theme Block--rapid-fire cases, simulation, skills workshops, peer mini-lectures. This is followed by small group discussions, with the goal of identifying barriers and benefits to implementing similar formats at one's home institution. After observing video of a peer-delivered session, a larger group discussion will address the three domains of resident/learner engagement--content creation, collaborative learning, and peer coaching—with associated examples of innovations in the MGH model to address these domains. Facilitators will unpack how Buprenorphine waiver training was delivered to all categorical and primary care residents in the MGH SUDs Theme Block. Finally, teaching micro skills that were highlighted by resident feedback will be reviewed in small group sessions.

    Devin Oller

    MD

    Devin Oller, MD is a graduate of Temple University School of Medicine, where he received the Thomas M Durant Prize in Internal Medicine. He completed his internal medicine residency at Massachusetts General Hospital, and was one of the inaugural fellows in Rural Health Leadership prior to returning to MGH as the Primary Care Chief Resident. He attends on MGH's inpatient Addictions Consult Team and the Bridge Clinic, a low-threshold model for delivering care to people who use drugs.

    Michael Bierer

    MD, MPH

    Michael F. Bierer MD MPH has been at Massachusetts General Hospital (MGH) for 30+ years. He holds the ranks of Physician there and Assistant Professor of Medicine at Harvard Medical School. He completed his MD at Albert Einstein College of Medicine in Bronx NY in 1985 and his MPH at Harvard School of Public Health in Boston MA in 1989. He completed his Internal Medicine Residency at MGH in 1988 and participated in the Addiction Medicine Fellowship in the Department of Psychiatry at Boston University Medical Center in 2001. He ran the component of Boston Health Care for the Homeless Program based at MGH from 1989-2001, has been providing integrated care for addictions in a hospital-based primary care practice since 2002, and has been a leader in the education of medical housestaff at MGH about drug and alcohol problems. He is part of the new Substance Use Disorders Iinitiative at the hospital. He is former Secretary of MASAM and serves currently as President. He is one of the podcast voices for the New England Journal of Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Opioid Use Disorders and the Americans with Disabilities Act: Eliminating Discriminatory Barriers to Treatment and Recovery (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to eliminate discriminatory barriers in treatment and recovery for patients with disabilities and opioid use disorders, from this conference recording from The ASAM 49th Annual Conference (2018). This session was made available free of charge by ASAM until 11/16/18.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn from an attorney from the Disability Rights Section in the U.S. Department of Justice’s Civil Rights Division will present on “Opioid Use Disorders and the Americans with Disabilities Act: Eliminating Discriminatory Barriers to Treatment and Recovery.” Among the topics discussed will be the Civil Rights Division’s response to the opioid epidemic; an Americans with Disabilities Act (ADA) overview; the ADA’s application to and protections for people with substance use disorders and opioid use disorders; and how to file a complaint about disability discrimination with the Department.

    Elizabeth Westfall

    JD

    Elizabeth Westfall, Deputy Chief, Disability Rights Section, Civil Rights Division, U.S. Department of Justice

    Elizabeth Westfall is a deputy chief of the Disability Rights Section in the Civil Rights Division of the U.S. Department of Justice.  Ms. Westfall leads the Section’s initiative under the Americans with Disabilities Act (ADA) to combat discrimination against people with opioid use disorder who are in treatment or recovery.  She also leads the Section’s enforcement of the ADA’s integration mandate.  

    From 2010 until 2015, Ms. Westfall served as a trial attorney in the Civil Rights Division’s Voting Section, where she litigated cases under the Voting Rights Act.  Prior to the Voting Section, Ms. Westfall held positions with non-profit civil rights organizations and a civil rights law firm in Washington, DC, where she litigated voting rights, fair housing, and employment discrimination cases.  Ms. Westfall is a graduate of Harvard Law School and Carleton College.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Addiction & MH Conditions in Healthcare Providers: Eval, Tx & Legal Considerations (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about physician burnout and suicide rates, as well as treatment options for physicians with substance use disorder, from this recording at The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that physician burnout and suicide rates are at their highest levels and steadily climbing. Workload, electronic medical records, decreased time with patients and poor work-life balance have all be proposed as possible contributors to the epidemic of physician burnout. In contrast, physicians have the same rates of mental illness (such as depression and anxiety) and substance abuse as the general population. However, the substance physicians tend to abuse are alcohol and prescription medications (v.s. illicit substances for the general pop). With all of these factors colliding into "Physician Health," it is no surprise that physician well-being committees are commonly tasked with assessing a "troubled physician".  Burnout and suicide are not limited to seasoned members of the field of medicine. Medical students and residents have burnout levels as high as 50%. We are just now starting to uncover the epidemic of medical student and resident suicide rates.  An intensive diagnostic evaluation of a physician is a repetitively new concept. Prior to the 1990's Physicians were confronted and in many cases forced into treatment. Currently, the practice is to encourage a physician suspected of having a substance abuse, mental health or behavioral problem into a minimum 72 hour diagnostic evaluation to uncover whether or not they need treatment.  Physicians face similar barriers to treatment as the general population such as shame. However, they also face barriers such as fear of losing their careers, losing medical malpractice coverage, losing credentialing/hospital privileges and more if they are diagnosed with mental illness or substance abuse.  Therefore, the delivery and quality of a diagnostic evaluation and treatment and monitoring for a physician are critical. Our workshop will cover the current healthcare environment and the epidemiological and other risk factors that physicians face. We will discuss the process of intervention and what to do when a colleague, staff member or resident/medical student is suspected of being impaired. In great detail we will cover the process of evaluating a physician from a multi-disciplinary approach. We will discuss the treatment process of when a healthcare provider (a colleague, staff member or resident/medical student) needs treatment including the intensity of treatment, levels of care, medication vs. non-medication treatment options, time needed off of work and other important considerations. Finally, in great detail we will cover the process of ongoing monitoring to assure the healthcare provider is safe to return and to continue to practice after receiving treatment. We will provide an interactive experience for the audience to help them incorporate a better understanding of both physician health and thorough treatment into their practice or into the medical institution. Legal consideration and concerns will be discussed and best practices will be provided.

    Matthew Goldenberg

    DO

    Matthew Goldenberg D.O. is an expert in the evaluation and treatment of mental health disorders and is an addiction specialist in Santa Monica, CA. He is double Board Certified in Psychiatry and Addiction Psychiatry. Dr. Goldenberg is the Associate Medical Director of Professional Health Services at Promises Treatment Centers. Dr. Goldenberg specializes in helping professionals (many of whom are healthcare providers) obtain and learn to maintain long-term recovery from drugs, alcohol and/or mental illness. In this capacity, Dr. Goldenberg assists in multi-disciplinary evaluations to help uncover if there is an underlying addiction or mental health condition and also provides treatment which includes individual medication and non-medication treatment options and group therapy facilitation. Dr. Goldenberg continues to engage in research and medical education as a member of the Medical Staff and as an Assistant Professor of Psychiatry at Cedars Sinai Medical Center, in Los Angeles, California. Dr. Goldenberg also maintains a small private practice in Santa Monica, CA. This affords the ability to provide highly individualized and evidence-based treatment to a select group of motivated patients.  Dr. Goldenberg completed an Addiction Psychiatry Fellowship through UCLA and Psychiatry Residency at Banner University Medical Center, of the University of Arizona, in Phoenix, Arizona. Dr. Goldenberg completed medical school at Midwestern University, Arizona College of Osteopathic Medicine. Dr. Goldenberg matriculated at Santa Clara University for his undergraduate education. 

    Karen Miotto

    MD

    Dr. Karen Miotto is a Clinical Professor in the Department of Psychiatry and Behavioral Sciences at UCLA, the Director of the UCLA Addiction Medicine Service, and Chair of the UCLA Medical Staff Health Program. Dr. Miotto is the Chair of California Public Protection & Physician Health (CPPPH) and is the Chair of the Committee on Wellbeing of Physicians of the California Society of Addiction Medicine (CSAM). She is dedicated to promoting physician wellness and educating others on how to reduce physician distress, burnout, substance misuse and mental illness in the medical profession. Additionally, Dr. Miotto is frequently an invited speaker at local and international addiction medicine meetings. She is the recipient of a career development award from the National Institute on Drug Abuse and is an investigator in the area of addiction pharmacology.

    Greg Skipper

    MD, DFASAM

    Dr. Skipper is a Distinguished Fellow of the American Society of Addiction Medicine and a certified Medical Review Officer. He is currently the director of Professional Health Services at Promises Professionals Treatment Program in Santa Monica CA. This treatment program is a separate Promises program that focuses on evaluation and treatment of professionals. Dr. Skipper has conducted over 2,000 in-depth evaluations on licensed professionals over the past 30 years. Dr. Skipper previously served as Medical Director of the Alabama Physician Health Program (1999-2011) and was on the council that created and oversaw the Oregon Health Professionals Program (1989-1993). Dr. Skipper was also the primary innovator of ethylglucuronide, EtG, testing, a superior drug test for detecting abstience from alcohol use, in the United States and abroad and is an expert in alcohol biomarkers and other drug testing. He was a principle investigator of The Blueprint Study, the most extensive National Study of Physician Health Programs, funded by a Robert Wood Johnson Foundation grant, and is the author of more than 100 articles and book chapters regarding drug testing, physician health and contingency monitoring. Dr. Skipper was formerly Medical Director of Springbrook Hazelden and he was a chief advisor to the designing of the professionals program at Betty Ford Center and Bradford Health Services. Dr. Skipper assisted in developing Physician Health Programs in Melbourne Australia and Salzburg Austria. Dr. Skipper is also Medical Director of an educational company, Professional Boundaries, Inc., that conducts over 80 courses per year nationally in major cities regarding Professional Boundaries, Medical Ethics, Apprpriate Prescribing and Medical Records. 

    Kevin D. Cauley

    JD

    Kevin D. Cauley is the founder of Kevin Cauley, P.C., located in Los Angeles, California. He represents physicians and other health care professionals who are facing disciplinary action with respect to their professional licenses.  Mr. Cauley's practice focuses on professional licensing, medical staff peer review, Medicare and Medi-Cal fraud and recoupment, health care contracting, and the defense of white collar offenses. He has worked in the field of professional licensure and health care law for over a decade.  

    Originally from Atlanta, Georgia, Mr. Cauley graduated magna cum laude from Oglethorpe University.  Prior to attending law school, he worked for several years as a paralegal with a well-known law firm focusing on the defense of health care and other licensed professionals. Having developed a strong interest in this field, he then attended Southwestern University School of Law and was awarded his Juris Doctor. While in law school, Mr. Cauley served as a managing editor of the Los Angeles Public Interest Law Journal, completed a public interest fellowship program at the Los Angeles Gay & Lesbian Center and was honored for his scholastic achievements with the Witkin Award for Academic Excellence. 
    Mr. Cauley is a member of the American Psychology-Law Society, California Academy of Attorneys for Healh Care Professionals, California Attorneys for Criminal Justice, and The American Association of Nurse Attorneys. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Addressing Complex Issues in Buprenorphine Prescribing: a Workshop (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the intricacies of prescribing buprenorphine, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that buprenorphine became available for the treatment of opioid dependence in the United States in 2002. The accompanying regulations also allowed that the treatment be done outside of Opioid Treatment Programs (OTPs) or methadone clinics in a variety of settings including office-based providers and various types of outpatient programs by physicians (and now advanced providers) who obtain X-waiver certification. While it is clear that buprenorphine is an effective treatment for patients with opioid dependence with retention in treatment, reduction in illicit opiate use, decreases in craving and improvements in function on a variety of levels supported as evidence-based outcomes various issues come up in prescribing patients buprenorphine. Some physicians ignore the problems and others have zero tolerance for any deviations from what is expected. In this workshop two physicians with many years’ experience from outpatient treatment programs, Emergency Departments, detoxification units and hospital settings as well as primary care practice, will present and moderate case-based discussions in addressing complex issues in buprenorphine prescribing. These issues include running out of medication early or encounters with patients who report lost or stolen medications. What does one do when the urine has been adulterated or substituted or does not show any buprenorphine? How should one optimally approach patients that are using other substances such as alcohol, cocaine, marijuana or prescription sedatives and benzodiazepines when prescribed buprenorphine? These issues are discussed and often debated yet typically don’t come to easy resolution. The authors of this workshop will present and moderate discussion for various cases and provide examples of and support for approaches for challenging patient encounters that providers prescribing buprenorphine are confronted with. The format is through moderated case discussion and the audience will be encouraged to present their thoughts and responses for discussion during this session as well. Where available references to support decision making and to clarify pharmacologic, toxicologic and forensic principles, such as interpretation of drug testing results, will be provided. Cases will also serve to reinforce basic addition medicine competencies in these areas though interactive discussion and presentation rather than didactic lecture.

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    Norman Wetterau

    MD, FASAM, FAAFP

    Dr. Wetterau is a practicing rural family physician whose practice is mainly addiction medicine. He is the Liaison from ASAM to AAFP, to the PCPCC, and co-chair of the STFM addiction interest group. He is immediate past president of NYSAM and co-chair of ASAM Chapters Council. He is also on the board of COPE (Coalition on Physician Education in Substance Abuse) and clinical assistant professor of family medicine at the University Rochester School of Medicine. In addition he teaches a annual course in behavioral health at Hope Africa Medical School in Burundi.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.